u/Less_Lynx3281

I’ve the impression that this penny stock is really under value. Any one of you have something to star ?

Here is the cold, hard data on why the current valuation is a complete joke, and exactly when the shorts are going to get trapped.
1. The Insane Enterprise Value (EV) Discount
Market Cap: ~$330M (at ~$5.37/share).

Cash & Short-term Investments: $168.3M (As of March 31, 2026).

Enterprise Value (EV): $161.7M Wall Street is valuing their entire FDA-approved manufacturing facility, their active commercial launch, their new solid tumor T-cell platform (ABO-701), and a functional commercial monopoly at just $161M. Bankruptcy or near-term dilution risk is mathematically 0%.

2. High-Octane Operating Leverage
In Q1 2026, Zevaskyn generated $8.72M in revenue (pulverizing the consensus forecast of $4.62M by over 88%).
The kicker: That $8.72M came from just 3 patients ($2.9M average per patient).

The margins: Cost of sales was only $2.7M, meaning they are pulling a massive ~69% gross margin on their first treatments. With quarterly recurring fixed costs (SG&A + core R&D) stabilized around $22M, their commercial break-even point is just 11 patients per quarter.

3. The Shorts are Trapped in a 22-Day Chokehold
According to official NASDAQ data, the Short Interest stands at a massive 30.64% of the float (16.49 million shares sold short). Because of the low average daily volume, the Days to Cover is a staggering 22.5 days (fintel shows a short volume ratio consistently above 50-60% over the last few days). They cannot squeeze through the exit door quietly.
Timeline of the Squeeze: When does the fuse ignite?
The disconnect exists because we are in a temporary visibility gap: the company has expanded its Qualified Treatment Centers (QTCs) to 6 active sites, but the cash hasn't fully hit the balance sheet yet. The short squeeze is highly likely to trigger in 3 distinct steps this year:
Step 1: The June 2026 Profitability Floor. Management explicitly reiterated on the May 13 call that they anticipate hitting monthly net profitability starting June 2026. Once June prints green, the "cash burn" narrative is dead, creating an unbreakable floor around $5.00 - $5.50. Borrow rates will start eating the shorts alive.

Step 2: The Mid-August Q2 Earnings Trigger. In Q1, all $8.72M came from only 2 active centers. For Q2, management confirmed 1 patient is already treated, 1 is in manufacturing, and 6 more are scheduled/expected for biopsies. That's a pipeline of 7 to 8 patients for Q2, projecting revenue near $20M - $23M. Printing a sequential 100%+ revenue growth will cut the quarterly net loss in half. Algos will buy aggressively, triggering margin calls for weak shorts as soon as we breach technical resistance at $7.50, pushing the stock to $10.

Step 3: November Q3 Capitulation. As their network scales toward 15 active centers by year-end, Q3 will be the first full quarter displaying structural net profitability. Trapped by a 22-day exit timeline, institutional shorts will be forced into a cascading buy-back panic.

Bottom line: Krystal Biotech ($KRYS), their direct competitor with a lifelong chronic application gel, is sitting on a $9.1B market cap. Abeona's curative, one-shot cell therapy just needs to capture a fraction of that execution to reach a $1B valuation, pushing the stock straight to $15+.
The spring is coiled tight. The August earnings will be the catalyst. Positioned before the crowd.

Here is the cold, hard data on why the current valuation is a complete joke, and exactly when the shorts are going to get trapped.
1. The Insane Enterprise Value (EV) Discount
Market Cap: ~$330M (at ~$5.37/share).

Cash & Short-term Investments: $168.3M (As of March 31, 2026).

Enterprise Value (EV): $161.7M Wall Street is valuing their entire FDA-approved manufacturing facility, their active commercial launch, their new solid tumor T-cell platform (ABO-701), and a functional commercial monopoly at just $161M. Bankruptcy or near-term dilution risk is mathematically 0%.

2. High-Octane Operating Leverage
In Q1 2026, Zevaskyn generated $8.72M in revenue (pulverizing the consensus forecast of $4.62M by over 88%).
The kicker: That $8.72M came from just 3 patients ($2.9M average per patient).

The margins: Cost of sales was only $2.7M, meaning they are pulling a massive ~69% gross margin on their first treatments. With quarterly recurring fixed costs (SG&A + core R&D) stabilized around $22M, their commercial break-even point is just 11 patients per quarter.

3. The Shorts are Trapped in a 22-Day Chokehold
According to official NASDAQ data, the Short Interest stands at a massive 30.64% of the float (16.49 million shares sold short). Because of the low average daily volume, the Days to Cover is a staggering 22.5 days (fintel shows a short volume ratio consistently above 50-60% over the last few days). They cannot squeeze through the exit door quietly.
Timeline of the Squeeze: When does the fuse ignite?
The disconnect exists because we are in a temporary visibility gap: the company has expanded its Qualified Treatment Centers (QTCs) to 6 active sites, but the cash hasn't fully hit the balance sheet yet. The short squeeze is highly likely to trigger in 3 distinct steps this year:
Step 1: The June 2026 Profitability Floor. Management explicitly reiterated on the May 13 call that they anticipate hitting monthly net profitability starting June 2026. Once June prints green, the "cash burn" narrative is dead, creating an unbreakable floor around $5.00 - $5.50. Borrow rates will start eating the shorts alive.

Step 2: The Mid-August Q2 Earnings Trigger. In Q1, all $8.72M came from only 2 active centers. For Q2, management confirmed 1 patient is already treated, 1 is in manufacturing, and 6 more are scheduled/expected for biopsies. That's a pipeline of 7 to 8 patients for Q2, projecting revenue near $20M - $23M. Printing a sequential 100%+ revenue growth will cut the quarterly net loss in half. Algos will buy aggressively, triggering margin calls for weak shorts as soon as we breach technical resistance at $7.50, pushing the stock to $10.

Step 3: November Q3 Capitulation. As their network scales toward 15 active centers by year-end, Q3 will be the first full quarter displaying structural net profitability. Trapped by a 22-day exit timeline, institutional shorts will be forced into a cascading buy-back panic.

Bottom line: Krystal Biotech ($KRYS), their direct competitor with a lifelong chronic application gel, is sitting on a $9.1B market cap. Abeona's curative, one-shot cell therapy just needs to capture a fraction of that execution to reach a $1B valuation, pushing the stock straight to $15+.
The spring is coiled tight. The August earnings will be the catalyst. Positioned before the crowd.

[removed]